Bédard D - Search Results

1

Levodopa-induced dyskinesia: a brief review of the ongoing clinical trials.

Huot P, Kang W, Kim E, Bédard D, Belliveau S, Frouni I, Kwan C. Huot P, et al. Among authors: bedard d. Neurodegener Dis Manag. 2022 Apr;12(2):51-55. doi: 10.2217/nmt-2021-0051. Epub 2021 Dec 23. Neurodegener Dis Manag. 2022. PMID: 34939425 Review. No abstract available.

2

Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method to quantify LY-354,740 in rat and marmoset plasma.

Gaudette F, Hamadjida A, Bédard D, Nuara SG, Beaudry F, Huot P. Gaudette F, et al. Among authors: bedard d. J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Sep 1;1061-1062:392-398. doi: 10.1016/j.jchromb.2017.07.007. Epub 2017 Jul 15. J Chromatogr B Analyt Technol Biomed Life Sci. 2017. PMID: 28802219

3

The highly selective 5-HT_2A antagonist EMD-281,014 reduces dyskinesia and psychosis in the l-DOPA-treated parkinsonian marmoset.

Hamadjida A, Nuara SG, Bédard D, Gaudette F, Beaudry F, Gourdon JC, Huot P. Hamadjida A, et al. Among authors: bedard d. Neuropharmacology. 2018 Sep 1;139:61-67. doi: 10.1016/j.neuropharm.2018.06.038. Epub 2018 Jun 30. Neuropharmacology. 2018. PMID: 29969592

4

Development of a selective and sensitive high-performance liquid chromatography-tandem mass spectrometry assay to support pharmacokinetic studies of LY-487,379 in rat and marmoset.

Gaudette F, Hamadjida A, Bédard D, Nuara SG, Gourdon JC, Michaud V, Beaudry F, Huot P. Gaudette F, et al. Among authors: bedard d. J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Sep 1;1093-1094:1-7. doi: 10.1016/j.jchromb.2018.06.036. Epub 2018 Jun 19. J Chromatogr B Analyt Technol Biomed Life Sci. 2018. PMID: 29980099

5

Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset.

Hamadjida A, Nuara SG, Bédard D, Frouni I, Kwan C, Gourdon JC, Huot P. Hamadjida A, et al. Among authors: bedard d. Naunyn Schmiedebergs Arch Pharmacol. 2018 Dec;391(12):1339-1345. doi: 10.1007/s00210-018-1549-6. Epub 2018 Aug 7. Naunyn Schmiedebergs Arch Pharmacol. 2018. PMID: 30088028

6

Effect of the selective 5-HT_2A receptor antagonist EMD-281,014 on L-DOPA-induced abnormal involuntary movements in the 6-OHDA-lesioned rat.

Frouni I, Kwan C, Bédard D, Belliveau S, Bourgeois-Cayer É, Gaudette F, Beaudry F, Hamadjida A, Huot P. Frouni I, et al. Among authors: bedard d. Exp Brain Res. 2019 Jan;237(1):29-36. doi: 10.1007/s00221-018-5390-4. Epub 2018 Oct 8. Exp Brain Res. 2019. PMID: 30298296

7

5-HT_2A blockade for dyskinesia and psychosis in Parkinson's disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review.

Kwan C, Frouni I, Bédard D, Nuara SG, Gourdon JC, Hamadjida A, Huot P. Kwan C, et al. Among authors: bedard d. Exp Brain Res. 2019 Feb;237(2):435-442. doi: 10.1007/s00221-018-5434-9. Epub 2018 Nov 15. Exp Brain Res. 2019. PMID: 30443669 Review.

8

Highly sensitive HPLC-MS/MS assay for the quantitation of ondansetron in rat plasma and rat brain tissue homogenate following administration of a very low subcutaneous dose.

Gaudette F, Bédard D, Kwan C, Frouni I, Hamadjida A, Beaudry F, Huot P. Gaudette F, et al. Among authors: bedard d. J Pharm Biomed Anal. 2019 Oct 25;175:112766. doi: 10.1016/j.jpba.2019.07.014. Epub 2019 Jul 12. J Pharm Biomed Anal. 2019. PMID: 31330277

9

Activation of mGlu_2/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism.

Frouni I, Hamadjida A, Kwan C, Bédard D, Nafade V, Gaudette F, Nuara SG, Gourdon JC, Beaudry F, Huot P. Frouni I, et al. Among authors: bedard d. Neuropharmacology. 2019 Nov 1;158:107725. doi: 10.1016/j.neuropharm.2019.107725. Epub 2019 Jul 25. Neuropharmacology. 2019. PMID: 31351976

10

Ondansetron, a highly selective 5-HT₃ receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.

Kwan C, Frouni I, Bédard D, Hamadjida A, Huot P. Kwan C, et al. Among authors: bedard d. Eur J Pharmacol. 2020 Mar 15;871:172914. doi: 10.1016/j.ejphar.2020.172914. Epub 2020 Jan 8. Eur J Pharmacol. 2020. PMID: 31926127

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

126 results

Search Page